Drugs / insulin 338
insulin 338
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT02304627 | Nov 2014 → Jul 2015 | diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT02220296 | Aug 2014 → Mar 2015 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01931137 | Aug → Dec 2013 | diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01796366 | Feb → Aug 2013 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02470039 | Jun → Dec 2015 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | insulin 338 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01931137 ↗ |
| Known as | GIPET I | “insulin 338 (GIPET I)” NCT02470039 ↗1“insulin 338 (GIPET I)” NCT01796366 ↗ |
| Known as | I338 | “Oral insulin 338 (I338) is a long-acting, basal insulin analogue formulated in a tablet with the absorption-enhancer sodium caprate.” PMID 30679095 ↗ Jan 2019 |
| Known as | NNC0123-0000-0338 | “The aim of the trial is to investigate the pharmacokinetics (the exposure of the trial drug in the body) and pharmacodynamics (the effect of the investigated drug on the body)...” NCT01931137 ↗1“NNC0123-0000-0338 (insulin 338)” NCT01796366 ↗ |
| Modality | Protein / enzyme biologic | “Oral insulin 338 is a novel tablet formulation of a long-acting basal insulin.” PMID 31093929 ↗ Nov 2019 |
| Route | Subcutaneous | “insulin 338 and placebo, administered subcutaneously” NCT01796366 ↗ |